Market cap
$8 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.3
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -13.10 | -20.99 | -375.65 | 11.35 | 5.87 |
| Net Profit | 112.20 | 113.05 | 32.50 | 14.88 | 7.88 |
| EPS | 105.91 | 103.78 | 46.71 | -3.41 | 0.53 |
| Book Value | -- | -- | -40.00 | -8.37 | -13.71 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -242.67 | -199.93 | -138.08 | -291.56 | -280.02 |
| Return on Capital
| -207.70 | -174.91 | -- | -231.66 | -245.69 |
| Return on Assets
| -166.71 | -144.59 | -69.96 | -169.21 | -205.38 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.22 | 0.29 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
--
|
-231.66
|
-245.69
|
-145.75
|
-136.35
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-138.08
Lower than Peers by 97.79
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
-138.08
|
-291.56
|
-280.02
|
-156.42
|
-146.53
|
|
Peer Median
|
-40.29
|
--
|
--
|
--
|
--
|
ROA
-69.96
Lower than Peers by 39.13
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
-69.96
|
-169.21
|
-205.38
|
-125.53
|
-119.01
|
|
Peer Median
|
-30.84
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-82.21
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-89.88
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
-375.65
Lower than Peers by 374.69
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
-375.65
|
38.93
|
-14.39
|
23.54
|
-17.15
|
|
Peer Median
|
-0.95
|
--
|
--
|
--
|
--
|
Net Profit Growth
32.50
Higher than Peers by 39.68
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
32.50
|
38.93
|
-14.39
|
23.67
|
-17.34
|
|
Peer Median
|
-7.19
|
--
|
--
|
--
|
--
|
EPS Growth
46.71
Higher than Peers by 32.28
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
46.71
|
0.58
|
-2.65
|
0.14
|
-0.27
|
|
Peer Median
|
14.43
|
--
|
--
|
--
|
--
|
Book Value Growth
24.08
Higher than Peers by 34.54
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
24.08
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.46
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
--
|
0.22
|
0.29
|
0.07
|
0.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.02
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
0.02
|
0.06
|
0.10
|
0.04
|
0.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
7.10
Higher than Peers by 1.30
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
7.10
|
1.29
|
5.67
|
3.36
|
5.00
|
|
Peer Median
|
5.80
|
--
|
--
|
--
|
--
|
Quick Ratio
7.10
Higher than Peers by 1.41
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
7.10
|
--
|
--
|
0.45
|
3.45
|
|
Peer Median
|
5.69
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
--
|
--
|
--
|
--
|
-611.04
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.07
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
--
|
--
|
4,646.61
|
3,492.43
|
3,063.24
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
--
|
--
|
558.12
|
646.01
|
1,095.33
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
--
|
-0.51
|
-0.29
|
-0.36
|
-0.60
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
1.28
Lower than Peers by 4.07
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
1.28
|
1.58
|
1.31
|
0.64
|
1.09
|
|
Peer Median
|
5.35
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.11
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
-0.11
|
-0.48
|
-0.08
|
-0.12
|
-0.27
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
8
Lower than Peers by 140
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
ENDRA Life Sciences (NDRA)
|
8
|
--
|
--
|
--
|
--
|
|
Peer Median
|
147
|
--
|
--
|
--
|
--
|